Description
Hepatitis Testing Markets
This report, Hepatitis Testing Markets, includes
Hepatitis Immunoassay Market, 2016 – 2021
Hepatitis Molecular Testing Market, 2016 -2021
Hepatitis Point of Care Markets, 2016-2021
Molecular Testing Market by Type (C, B, A and Others)
Key Trends in the Market
Geographic Breakout of Market (US, ROW)
Company Profiles
HCV in particular is a driver of sales in this market. While HCV infections are increasingly caught and treated among baby boomers (a fact easily observable in Medicare billings), U.S. HCV incidence is also sharply increasingly among younger generations or individuals 20-39 years of age. Intravenous drug use is again the cause of rising HCV cases in this age group as well.
Molecular diagnostics is unrivaled among the IVD technologies used for infectious disease testing in terms of its performance and applicability. Microarray, next-generation sequencing and development-stage isothermal amplification methods represent promising contributions to the market space. For the time being, PCR and isothermal amplification tests represent the bulk of the market with assay development proceeding faster than ever using genomic science tools, microfluidics, machine automation, and novel forms of results detection. Immunoassays are more often used for the initial detection of hepatitis infections, but with the increasing significance of hepatitis in healthcare and the development of sophisticated antiviral therapeutics, molecular tests are becoming just as integral to clinical hepatitis treatment.
